Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 184150-96-7 | MDL No. : | MFCD18381247 |
Formula : | C11H11NO2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | BGEBSRRTTLVBFL-UHFFFAOYSA-N |
M.W : | 189.21 | Pubchem ID : | 11435419 |
Synonyms : |
|
Num. heavy atoms : | 14 |
Num. arom. heavy atoms : | 9 |
Fraction Csp3 : | 0.18 |
Num. rotatable bonds : | 2 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 54.54 |
TPSA : | 42.09 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.82 cm/s |
Log Po/w (iLOGP) : | 2.08 |
Log Po/w (XLOGP3) : | 2.3 |
Log Po/w (WLOGP) : | 2.26 |
Log Po/w (MLOGP) : | 1.67 |
Log Po/w (SILICOS-IT) : | 2.83 |
Consensus Log Po/w : | 2.23 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.81 |
Solubility : | 0.296 mg/ml ; 0.00156 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.82 |
Solubility : | 0.285 mg/ml ; 0.00151 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.75 |
Solubility : | 0.0337 mg/ml ; 0.000178 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.52 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
83% | With palladium diacetate; copper(II) acetate monohydrate In dimethyl sulfoxide at 80℃; for 48 h; Sealed tube; Inert atmosphere | prepared a degass ed mixture of compound LVI (10.0 g, 0.061 mol) and copper(II) acetate 10 monohydrate (36.2 g, 0.182 mol) in dimethyls ulfoxide (50 mL). To the flask was added acetone (100 mL), followed by palladium(II) acetate (0.270 g, 0.001 mol), and the resulting reaction mixture was heated at 80 °C for 48 h. After cooling to room temperature, the reaction mixture was filtered through a pad of celite and the filtrate w as diluted with water (80 mL). The aqueous mixture w as extracted with ethyl acetate (3 x 100 mL) and the 148 of 363 {//-- DRAFT --//4069/3020WO/00228726/v2} 4069.3020 WO combined organic extracts were dried over anhydrous sodium sulfate. The organic layer was concentrated under reduced pressure to obtain the crude product mixture, which was purified by silica gel chromatography using a gradient of 5-7percent ethyl acetate in hexanes as the eluant to affod LVII (4.8 g, 83percent) as a pale yellow solid.1H NMR (400 MHz, CDCl3) δ 8.26 (brs, 5 1H), 8.04 (s, 1H), 7.77 (dd, J= 8.3, 3.4 Hz, 1H), 7.50 (d, J= 8.3 Hz, 1H), 6.26 (s, 1H), 3.92 (s, 3H), 2.47 (s, 3H); MS (ESI, positive mode) m/z 190 (MH+). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
303 mg | at 100℃; for 8 h; | To a solution of the compound [69-2] obtained in the process (2) (589 mg) in acetic acid (5 mL) were added iron powder (691 mg), and then the reaction mixture was stirred at 100°C for 8 hours. After cooling to room temperature, the insoluble materials were filtered, and the filtrate was concentrated under reduced pressure. The residue was added water, and extracted with ethyl acetate. The obtained organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography to give the titled compound (303 mg) as a brown solid. 1H-NMR (400 MHz, CDCl3) δ: 8.21-8.20 (1H, br), 8.04 (1H, s), 7.77 (1H, dd, J = 8.5, 1.5 Hz), 7.51 (1H, d, J = 8.3 Hz), 6.28-6.27 (1H, m), 3.92 (3H, s), 2.49 (3H, s). |
[ 880360-85-0 ]
Methyl 2-formyl-1H-indole-5-carboxylate
Similarity: 0.98
[ 1011-65-0 ]
Methyl 1H-indole-5-carboxylate
Similarity: 0.98
[ 50820-65-0 ]
Methyl 1H-indole-6-carboxylate
Similarity: 0.98
[ 21987-27-9 ]
Methyl 2,3-dimethyl-1H-indole-5-carboxylate
Similarity: 0.97
[ 184151-49-3 ]
Methyl 3-methyl-1H-indole-6-carboxylate
Similarity: 0.95
[ 880360-85-0 ]
Methyl 2-formyl-1H-indole-5-carboxylate
Similarity: 0.98
[ 1011-65-0 ]
Methyl 1H-indole-5-carboxylate
Similarity: 0.98
[ 50820-65-0 ]
Methyl 1H-indole-6-carboxylate
Similarity: 0.98
[ 21987-27-9 ]
Methyl 2,3-dimethyl-1H-indole-5-carboxylate
Similarity: 0.97
[ 184151-49-3 ]
Methyl 3-methyl-1H-indole-6-carboxylate
Similarity: 0.95